Pharmacotherapy of major depression in late life: what is the role of new agents?

References

• Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry. 2009;66(8):848–856.
   PubMed Web of Science ®Google Scholar
• Alexopoulos GS, Katz IR, Reynolds CF, et al. Pharmacotherapy of depression in older patients: a summary of the expert consensus guidelines. J Psychiatr Pract. 2001;7(6):361–376.
   PubMedGoogle Scholar
• Baldwin R, Chiu E, Katona C, et al. Guidelines on depression in older people. Boca Raton, FL: Taylor & Francis Group; 2002.
   Google Scholar
• Buchanan D, Tourigny-Rivard MF, Cappeliez P, et al. National guidelines for seniors’ mental health: the assessment and treatment of depression. Can J Psychiatry. 2006;9(Suppl2):S52–8.
   Google Scholar
• Canadian Coalition for Senior’s Mental Health. National guidelines for seniors’ mental health – the assessment and treatment of depression. 2006. Available at: http://ccsmh.ca/ccsmh-national-guidelines-for-seniors-mental-health/[Last accessed on 31 October 2016]
   Google Scholar
• American Psychiatric Association, Washington, DC. Practice guideline for the treatment of patients with major depressive disorder, 3rd Ed. Last Accessed on 2016 November 26. Available from: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf.
   Google Scholar
• Cleare A, Pariante CM, Young AH, et al. Members of the consensus meeting. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29(5):459–525.
   PubMed Web of Science ®Google Scholar
• MacQueen GM, Frey BN, Ismail Z, et al. the CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder section 6. Special populations: youth, women, and the elderly. Can J Psychiatry. 2016;61(9):588–603.
   PubMed Web of Science ®Google Scholar
• Mulsant BH, Blumberger DM, Ismail Z, et al. A systematic approach to pharmacotherapy for geriatric major depression. Clin Geriatr Med. 2014;30(3):517–534.
   PubMed Web of Science ®Google Scholar
• Dolder C, Nelson M, Stump A. Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients. Drugs Aging. 2010;27(8):625–640.
   PubMed Web of Science ®Google Scholar
• Cooper C, Katona C, Lyketsos K, et al. A systematic review of treatments for refractory depression in older people. Am J Psychiatry. 2011;168(7):681–688.
   PubMed Web of Science ®Google Scholar
• Nelson JC, Delucchi K, Schneider LS. Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry. 2008;16(7):558–567.
   PubMed Web of Science ®Google Scholar
• Rajji TK, Mulsant BH, Lotrich FE, et al. Use of antidepressants in late-life depression. Drugs Aging. 2008;25(10):841–853.
   PubMed Web of Science ®Google Scholar
• Unützer J, Katon W, Callahan CM, et al. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. Jama. 2002;288(22):2836–2845.
   PubMed Web of Science ®Google Scholar
• Alexopoulos GS, Reynolds CF, Bruce M, et al. The PROSPECT Group. Reducing suicidal ideation and depression in older primary care patients: 24-month outcomes of the PROSPECT study. Am J Psychiatry. 2009;166(8):882–890.
   PubMed Web of Science ®Google Scholar
• Guo T, Xiang YT, Xiao L, et al. Measurement-based care versus standard care for major depression: a randomized controlled trial with blind raters. Am J Psychiatry. 2015;172(10):1004–1013.
   PubMed Web of Science ®Google Scholar
• Mulsant BH, Alexopoulos GS, Reynolds CF, et al. Pharmacological treatment of depression in older primary care patients: the PROSPECT algorithm. Int J Geriatr Psychiatry. 2001;16(6):585–592.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration, 2012. FDA drug safety communication: revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm. [Last accessed 13 November 2016]
   Google Scholar
• Health Canada, 2012. Antidepressant Cipralex (escitalopram): updated information regarding dose-related heart risk. Available at: http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2012/13674a-eng.php. [Last accessed 13 November 2016]
   Google Scholar
• Vieweg WV, Hasnain M, Howland RH, et al. Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? Am J Med. 2012;125(9):859–868.
   PubMed Web of Science ®Google Scholar
• Castro VM, Clements CC, Murphy SN, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. Bmj. 2013;346:f288.
   PubMed Web of Science ®Google Scholar
• Zivin K, Pfeiffer PN, Bohnert AS, et al. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatry. 2013;170(6):642–650.
   PubMed Web of Science ®Google Scholar
• Danielsson B, Collin J, Jonasdottir Bergman G, et al. Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults – a Swedish nationwide study. Br J Clin Pharmacol. 2016;81(4):773–778.
   PubMed Web of Science ®Google Scholar
• Qirjazi E, McArthur E, Nash DM, et al. Risk of ventricular arrhythmia with citalopram and escitalopram: a population-based study. Plos One. 2016;11(8):1–18.
   Web of Science ®Google Scholar
• Ray WA, Chung CP, Murray KT, et al. High-dose citalopram and escitalopram and the risk of out-of-hospital death. J Clinc Psychiatry. 2016. published online 11 October 2016. DOI:10.4088/JCP.15m10324
   PubMed Web of Science ®Google Scholar
• Rector TS, Adabag S, Cunningham F, et al. Outcomes of citalopram dosage risk mitigation in a veteran population. Am J Psychiatry. 2016;173(9):896–902.
   PubMed Web of Science ®Google Scholar
• Mulsant BH, Houck PR, Gildengers AG, et al. What is the optimal duration of a short-term antidepressant trial when treating geriatric depression? J Clin Psychopharm. 2006;26(4):113–120.
   PubMed Web of Science ®Google Scholar
• Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27(4):215–223.
   PubMed Web of Science ®Google Scholar
• Robinson M, Oakes TM, Raskin J, et al. Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo. Am J Geriatr Psychiatry. 2014;22(1):34–45.
   PubMed Web of Science ®Google Scholar
• Kasper S, De Swart H, Andersen HF. Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry. 2005;13(10):884–891.
   PubMed Web of Science ®Google Scholar
• Bose A, Li D, Gandhi C. Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am J Geriatr Psychiatry. 2008;16(1):14–20.
   PubMed Web of Science ®Google Scholar
• Gorwood P, Weiller E, Lemming O, et al. Escitalopram prevents relapse in older patients with major depressive disorder. Am J Geriatr Psychiatry. 2007;15(7):581–593.
   PubMed Web of Science ®Google Scholar
• Bech P, Fava M, Trivedi MH, et al. Outcomes on the pharmacopsychometric triangle in bupropion‐SR vs. buspirone augmentation of citalopram in the STAR* D trial. Acta Psychiat Scand. 2012;125(4):342–348.
   PubMed Web of Science ®Google Scholar
• Sahli ZT, Banerjee P, Tarazi FI. The preclinical and clinical effects of vilazodone for the treatment of major depressive disorder. Expert Opin Drug Dis. 2016;11(5):515–523.
   PubMed Web of Science ®Google Scholar
• Croft HA, Pomara N, Gommoll C, et al. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2014;75(11):1291–1298.
   PubMed Web of Science ®Google Scholar
• Chen L, Greenberg WM, Gommoll C, et al. Levomilnacipran pharmacokinetics in healthy volunteers versus patients with major depressive disorder and implications for norepinephrine and serotonin reuptake inhibition. Clin Ther. 2015;37(9):2059–2070.
   PubMed Web of Science ®Google Scholar
• Rizvi SM, Shaikh S, Khan M, et al. Fetzima (levomilnacipran), a drug for major depressive disorder as a dual inhibitor for human serotonin transporters and beta-site amyloid precursor protein cleaving enzyme-1. CNS Neurol Disord Drug Targets. 2014;13(8):1427–1431.
   PubMed Web of Science ®Google Scholar
• Chen L, Boinpally R, Gad N, et al. Evaluation of cytochrome P450 (CYP) 3A4-based interactions of levomilnacipran with ketoconazole, carbamazepine or alprazolam in healthy subjects. Clin Drug Investig. 2015;35(10):601–612.
   PubMed Web of Science ®Google Scholar
• Citrome L. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2013;67(11):1089–1104.
   PubMed Web of Science ®Google Scholar
• Mørk A, Pehrson A, Brennum LT, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012;340(3):666–675.
   PubMed Web of Science ®Google Scholar
• Chen G, Lee R, Højer AM, et al. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig. 2013;33(10):727–736.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014;17(10):1557–1567.
   PubMed Web of Science ®Google Scholar
• Mahableshwarkar AR, Zajecka J, Jacobson W, et al. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacol. 2015;40(8):2025–2037.
   PubMed Web of Science ®Google Scholar
• Desta Z, Moaddel R, Ogburn ET, et al. Stereoselective and regiospecific hydroxylation of ketamine and norketamine. Xenobiotica. 2012;42(11):1076–1087.
   PubMed Web of Science ®Google Scholar
• Singh JB, Fedgchin M, Daly EJ, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173(8):816–826.
   PubMed Web of Science ®Google Scholar
• Zanos P, Moaddel R, Morris PJ, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533:481–486.
   PubMed Web of Science ®Google Scholar
• Murrough JW, Soleimani L, DeWilde KE, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015;45(16):3571–3580.
   PubMed Web of Science ®Google Scholar
• Wan LB, Levitch CF, Perez AM, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015;76(3):247–252.
   PubMed Web of Science ®Google Scholar
• Hu YD, Xiang YT, Fang JX, et al. Single iv ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychol Med. 2016;46(03):623–635.
   PubMed Web of Science ®Google Scholar
• Aan Het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67(2):139–145.
   PubMed Web of Science ®Google Scholar
• Lapidus KA, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014;76(12):970–976.
   PubMed Web of Science ®Google Scholar
• Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134–1142.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Weiller E. Real-world determinants of adjunctive antipsychotic prescribing for patients with major depressive disorder and inadequate response to antidepressants: a case review study. Adv Ther. 2015;32(5):429–444.
   PubMed Web of Science ®Google Scholar
• Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015;76(9):1232–1240.
   PubMed Web of Science ®Google Scholar
• Andreescu C, Mulsant BH, Peasley-Miklus C, et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. J Clin Psychiatry. 2007;68(2):194–200.
   PubMed Web of Science ®Google Scholar
• Meyers BS, Flint AJ, Rothschild AJ, et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry. 2009;66(8):838–847.
   PubMed Web of Science ®Google Scholar
• Nelson JC, Thase ME, Bellocchio EE, et al. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy. Int Clin Psychopharmacol. 2012;27(3):125–133.
   PubMed Web of Science ®Google Scholar
• Han C, Wang SM, Kwak KP, et al. Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: a 6-week, randomized, rater-blinded, prospective study. J Psychiatr Res. 2015;66:84–94.
   PubMed Web of Science ®Google Scholar
• Zhou X, Ravindran AV, Qin B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry. 2015;76(4):487–498.
   PubMed Web of Science ®Google Scholar
• Kamijima K, Higuchi T, Ishigooka J, et al. ADMIRE study group. Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study). J Affect Disord. 2013;151(3):899–905.
   PubMed Web of Science ®Google Scholar
• Rutherford B, Sneed J, Miyazaki M, et al. An open trial of aripiprazole augmentation for SSRI non‐remitters with late‐life depression. Int J Geriatr Psychiatry. 2007;22(10):986–991.
   PubMed Web of Science ®Google Scholar
• Sheffrin M, Driscoll HC, Lenze EJ, et al. Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission. J Clin Psychiatry. 2009;70(2):208–213.
   PubMed Web of Science ®Google Scholar
• Steffens DC, Nelson JC, Eudicone JM, et al. Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis. Int J Geriatr Psychiatry. 2011;26(6):564–572.
   PubMed Web of Science ®Google Scholar
• Lenze EJ, Mulsant BH, Blumberger DM, et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(10011):2404–2412.
   PubMed Web of Science ®Google Scholar
• Kaneriya SH, Robbins-Welty GA, Smagula SF, et al. Predictors and moderators of remission with aripiprazole augmentation in treatment-resistant late-life depression: an analysis of the IRL-GRey randomized clinical trial. JAMA Psychiatry. 2016;73(4):329–336.
   PubMed Web of Science ®Google Scholar
• Smagula SF, Wallace ML, Anderson SJ, et al. Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder. J Psychiatr Res. 2016;81:112–118.
   PubMed Web of Science ®Google Scholar
• Bauer M, Dell’Osso L, Kasper S, et al. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. J Affect Disord. 2013;151(1):209–219.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Bandelow B, Demyttenaere K, et al. Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies. Int J Neuropsychopharmacol. 2013;16(8):1733–1744.
   PubMed Web of Science ®Google Scholar
• Vieta E, Bauer M, Montgomery S, et al. Pooled analysis of sustained response rates for extended release quetiapine fumarate as monotherapy or adjunct to antidepressant therapy in patients with major depressive disorder. J Affect Disord. 2013;150(2):639–643.
   PubMed Web of Science ®Google Scholar
• Zhou X, Keitner GI, Qin B, et al. Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis. Int J Neuropsychopharmacol. 2015;18(11):pyv060.
   Google Scholar
• Dell’Osso B, Palazzo MC, Oldani L, et al. The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects. CNS Neurosci Ther. 2011;17(6):723–732.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Altamura AC, Katila H, et al. Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels. Int Clin Psychopharmacol. 2014;29(2):93–105.
   PubMed Web of Science ®Google Scholar
• Katila H, Mezhebovsky I, Mulroy A, et al. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate(quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry. 2013;21(8):769–784.
   PubMed Web of Science ®Google Scholar
• Beyer JL, Weisler RH. Adjunctive brexpiprazole for the treatment of major depressive disorder. Expert Opin Pharmacother. 2016. published online 27 October 2016. DOI:10.1080/14656566.2016.1254188
   PubMed Web of Science ®Google Scholar
• Nelson JC. The role of stimulants in late-life depression. Am J Psychiatry. 2015;172(6):505–507.
   PubMed Web of Science ®Google Scholar
• Lavretsky H, Kim MD, Kumar A, et al. Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. J Clin Psychiatry. 2003;64(12):1410–1414.
   PubMed Web of Science ®Google Scholar
• Lavretsky H, Park S, Siddarth P, et al. Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial. Am J Geriatr Psychiatry. 2006;14(2):181–185.
   PubMed Web of Science ®Google Scholar
• Lavretsky H, Reinlieb M, St Cyr N, et al. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172(6):561–569.
   PubMed Web of Science ®Google Scholar
• Roose S, Rutherford B. Cardiac effects of methylphenidate. Am J Psychiatry. 2015;172(10):1023.
   PubMed Web of Science ®Google Scholar
• Butters MA, Whyte E, Nebes RD, et al. The nature and determinants of neuropsychological functioning in late-life depression. Arch Gen Psychiatry. 2004;61(6):587–595.
   PubMed Web of Science ®Google Scholar
• Schiff GD, Galanter WL, Duhig J, et al. Principles of conservative prescribing. Arch Intern Med. 2011;171(16):1433–1440.
   PubMedGoogle Scholar
• Karp JF, Butters MA, Begley AE, et al. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry. 2014;75(8):785–793.
   PubMed Web of Science ®Google Scholar
• Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013–1022.
   PubMed Web of Science ®Google Scholar